KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cme (CME) Gross Profit (2016 - 2025)

Historic Gross Profit for Cme (CME) over the last 17 years, with Q3 2025 value amounting to $1.5 billion.

  • Cme's Gross Profit fell 260.17% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 billion, marking a year-over-year increase of 657.76%. This contributed to the annual value of $5.9 billion for FY2024, which is 1055.48% up from last year.
  • Per Cme's latest filing, its Gross Profit stood at $1.5 billion for Q3 2025, which was down 260.17% from $1.6 billion recorded in Q2 2025.
  • In the past 5 years, Cme's Gross Profit registered a high of $1.6 billion during Q2 2025, and its lowest value of $1.1 billion during Q3 2021.
  • Moreover, its 5-year median value for Gross Profit was $1.3 billion (2023), whereas its average is $1.3 billion.
  • Its Gross Profit has fluctuated over the past 5 years, first crashed by 1695.42% in 2021, then surged by 2018.33% in 2023.
  • Over the past 5 years, Cme's Gross Profit (Quarter) stood at $1.1 billion in 2021, then increased by 4.35% to $1.1 billion in 2022, then rose by 20.18% to $1.3 billion in 2023, then rose by 7.29% to $1.4 billion in 2024, then increased by 3.32% to $1.5 billion in 2025.
  • Its Gross Profit stands at $1.5 billion for Q3 2025, versus $1.6 billion for Q2 2025 and $1.6 billion for Q1 2025.